Volume : 10, Issue : 07, July – 2023
Title:
26.QBD APPROACH FOR METHOD DEVELOPMENT AND VALIDATION OF TIVOZANIB BULK DRUG AND IT’S FORMULATION BY USING RP-HPLC
Authors :
Miss. Shivani Ravindra Wagh, Prof. R. J. Jadhav
Attempts were made to develop RP-HPLC method for estimation of Tivozanib from tablet. For the RP – HPLC Agilent (S.K) method Gradient System UV Detector and C18 column with 250mm x4.6 mm i.d and 5μm particle size methanol: Methanol+0.05% OPA (80+20% v/v) was used as the mobile phase for the method. The detection wavelength was 220 nm and flow rate was 0.8 ml/min. In the developed method, the retention time of Tivozanib were found to be 4.280 min.The developed method was validated according to the ICH guidelines. The linearity, precision, range, robustness was within the limits as specified by the ICH guidelines. Hence the method was found to be simple, accurate, precise, economic and reproducible. So, it is worthwhile that, the proposed methods can be successfully utilized for the routine quality control analysis Tivozanib in bulk drug as well as in formulations.
Keywords: Tivozanib, RP-HPLC, Chromatogram.
Cite This Article:
Please cite this article in Shivani Ravindra Wagh et al, QBD Approach For Method Development And Validation Of Tivozanib Bulk Drug And It’s Formulation By Using RP-HPLC., Indo Am. J. P. Sci, 2023; 10 (07).
Number of Downloads : 10
References:
1. ICH Q8 (R2), Pharmaceutical Development, Part I: Pharmaceutical Development., 2009 http://www.ich.org/LOB/media//MEDIA4986.pdf.
2. ICH Q10, 2008. Pharmaceutical Quality Systems., http://www.ich.org
3. US Food and Drug Administration (FDA), Department of Health and Human Services, Pharmaceutical Quality for the 21st Century A Risk-Based Approach Progress Report, (2013)
4. US Food and Drug Administration (FDA), Guidance for industry PAT-A framework for innovative pharmaceutical manufacturing and quality assurance, FDA, Washington, DC, USA, (2004)
5. Trivedi B., Quality by design (QbD) in pharmaceuticals. Int J Pharm an Pharm Sci 4(1), 17-29
6. Serena O., Sergio P., Andra F, Application of quality by design to the development of analytical separation methods. Anal Bioanal Chem. 2012
7. Bhutani H., Kurmi M., Singh S., Beg S., Singh B., 2014.Quality by Design (QbD) in Analytical Sciences: An Overview. Pharma Times 46 (08), 71-75.
8. Reid G. L., Morgado J., Barnett K., Harrington B., Wang J., Harwood J., Fortin D., 2013. Analytical Quality by Design (AQbD) in Pharmaceutical Development. Amer Pharm Rev, 1-17.
9. Rozet E., Lebrun P., Debrus B., Boulanger B., Hubert P., 2013. Design Spaces for analytical methods. Trends in Analytical Chemistry 42, 157-167.
10. Molnar I., Rieger H.J., Monks K.E., 2010. Aspects of the “Design Space” in high pressure liquid chromatography method Development. J Chrom Anal 1217, 3193–3200.
11. Monks, K.E., Rieger, H.J., Molnar, I. Expanding the term “Design Space” in high performance liquid chromatography (I). J. Pharm. Biomed. Anal. 2011, 56 (5), 874879.
12. Sangshetti J. N., Deshpande M., Zaheer Z., Shinde D. B., Arote R, Quality by design approach: Regulatory need. Arab J Chem, 2014, 1-14.
13. Sumithra M., Ravichandiran V, Review on Quality by Design. Int J Front Sci Tech, 2015.2(4), 47-56.
14. Bhatt D.A., Rane S.I., “Qbd Approach to Analytical RP-HPLC Method Development and its Validation. Int J Pharm Pharm Sci 2011 3(1), 179-187.
15. Schmidt. A. H., Molnár I., Using an innovative Quality-by-Design approach for development of a stability indicating UHPLC method for ebastine in the API and pharmaceutical formulations. J Pharm Biomed Anal 2013,78(79), 65– 74.
16. Sanford, Boltan., Charl, S. Bon.,. Factorial Design. Pharmaceutical Statistics Practical and Clinical Application. fourth edition. 2004, pp 265-285.
17. Armstrong N., Kenneth C., James, Factorial Design of experiments. Pharmaceutical experimental design and interpretation, London, 1996, pp. 131-162.
18. Box GEP, Behnken DW. Some new three levels designs for the study of Quantitative variables. Technometrics 1960; 2(4):455 -75.
19. Synder, L., R., Kirland, J.,J., Glajch, Introduction to Modern Liquid Chromatography, 2nd edition, Wiley Inter science, New York,1997; P. 165.
20. Vibha Gupta, Ajay Deep Kumar Jain, N. S. Gill1, Kapil Gupta, Development and validation of HPLC method – a review.International Research Journal of Pharmaceutical and Applied Sciences,2012; 2(4): P.17-25.
21. Sethi, P., D., High performance liquid chromatography quantitative analysis of pharmaceutical formulations, 1st edition, New Delhi, CBS Publishers and Distributors, vol. 1, 2001; P. 3-4, 11,117-20.
22. Gurdeep, R., Chatwal, Sham, K., Anand., Instrumental methods of chemical analysis, 5th edition, Mumbai, Delhi, Bangalore, Nagpur, Hyderabad: Himalaya Publishing House, 2005; P. 2.566-8, 2.626-8.
23. Cazes, Scott R., P., Marcel Dekker, Chromatography Theory, 10th edition, Inc., New York, 2002; P. 4-45.
24. Godwin, W., Fong, Stanley, K., Lam., HPLC in the pharmaceutical industry, New York, CRC Press, Vol.3, 2010; P. 47.
25. Raynord, P., W., Liquid Chromatography for the Analyst,4th edition, Marcel Dekker Inc., New York, 1994; P. 323.
26. Dr. Ravi Sankar S., Text book of pharmaceutical analysis, 3rd edition, Tirunelveli, Rx Publications, 2005; P. 18.8-18.9.
27. Kasture, A., V., Mahadik, K., R., Text book of Pharmaceutical Analysis, vol.2, NiraliPrakashan, 2007; P. 48-57.
28. Beckett, A.,H., Stenlake, J.,B., Practical pharmaceutical chemistry,4th edition, New Delhi, CBS publishers and distributors, 1997;P. 138-43.
29. Braithwaite, Smith, Chromatography Methods, 5th edition, Kluwer Academi Publishers, USA, 1999; P. 2-43.
30. Azim Md. Sabir, HPLC Method development and validation, International Research Journal of Pharmacy, P.40-46.
</div8